<DOC>
	<DOCNO>NCT02769169</DOCNO>
	<brief_summary>The purpose study determine whether double-dose Ranibizumab effective regress polyp benefit visual outcome polypoidal choroidal vasculopathy ( PCV ) .</brief_summary>
	<brief_title>Double-dose Ranibizumab Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description>Recently , 's report intravitreal high dose Lucentis®（Ranibizumab） could benefit regression polyp relief macular edema PCV patient . Since single arm prospective study relatively small sample size , randomize clinical trial need confirm efficacy high dose Ranibizumab PCV treatment . In study , investigator compare efficacy double-dose ( 1mg , 3+prn ) Raibizumab regular dose ( 0.5mg , 3+prn ) PCV treatment .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age ≥ 50 year ≤80 ; Active PCV confirm ICGA+FFA ( Indocyanine green angiography + fundus fluorescein angiography ) ; At least one distinguishable polyp show ICGA ; BCVA 24 73 letter ETDRS chart ( Early Treatment Diabetic Retinopathty Study ) ; The great linear dimension lesion &lt; 5400μm . Previously receive treatment laser retina photocoagulation , transpupillary thermotherapy , pneumatic displacement subretinal blood investigational treatment ; Previous photodynamic therapy antiVegf treatment within 6 month study eye Previously receive treatment photodynamic treatment within 1 month , antivascular endothelial growth factor ( VEGF ) intraocular injection 3 month fellow eye ; Combine current vitreous hemorrhage extensive subretinal hemorrhage ( lesion area &gt; 30mm2 ) ; A history angioid streak , presume ocular histoplasmosis syndrome pathologic myopia ; Experienced retinal pigmental epithelium ( RPE ) tear , retinal detachment , macular hole uncontrolled glaucoma ; Undergone intraocular surgery ( except uncomplicated cataract extraction intraocular lens implantation ) ; Cataract extraction intraocular lens implantation within 60 day ; Combine cataract could require medical surgical intervention 12 month ; Combine diabetes mellitus poor glucose control ( Haemoglobin A1c ( HbA1c ) &gt; 8 % ) ; Combine hypertension poor blood pressure control ( blood pressure ≥140/95 mmHg regular antihypertensive drug treatment ) ; History myocardial infarction cerebral infarction last 6 month ; During gestation period lactation period ; Combine confirm systemic autoimmune disease uncontrollable clinical condition ( e.g . HIV , malignant tumor , active hepatitis , severe systemic disease , diseases need immediately surgical treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Ranibizumab , regression polyp</keyword>
</DOC>